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Abstract
A capillary electrophoresis (CE) method was developed for the stereoselective determination of the non-steroidal
anti-inflammatory drug (NSAID), S-naproxen, in tablets. Several b-cyclodextrin derivatives (CDs) were tested as
chiral selectors, including sulfobutyl-b-CD (SBCD), carboxymethyl-b-CD (CMCD), dimethyl-b-CD (DMCD) and
trimethyl-b-CD (TMCD), in a phosphoric acid:triethanolamine pH 3 buffer. Under these conditions, the analyte was
mainly present in an uncharged form and therefore, the use a neutral CD (DMCD or TMCD) alone could not lead
to enantiomeric separation. On the contrary, by addition of a charged CD (SBCD or CMCD) to the running buffer,
giving the analyte enantiomers an adequate mobility, chiral resolution could be achieved, although the resolution
values obtained in this case were not quite satisfactory (RsB1.5). Dual systems, based on the use of mixtures of
charged and neutral CDs, were then investigated. The SBCD:TMCD system was found to be particularly well suited
to the enantioseparation of naproxen and after optimisation of the concentrations of both CDs, a resolution value of
5.4 could be obtained. The method was validated for the determination of R-naproxen (enantiomeric impurity) in the
0.1–2% range, using the racemic mixture of the analyte. A second validation was performed in the 50–150% range
for the quantitation of S-naproxen. In both cases, good results with respect to linearity, precision and accuracy were
obtained. © 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
The quality control of drugs requires the devel-
opment of assays to control identity, potency or
strength, and purity. For drugs that contain one
or more stereogenic centers, the chiral purity may
be an important component in the determination
of purity and stability. A variety of chiral assay
techniques are available to the analyst including
nuclear magnetic resonance (NMR), infrared
spectroscopy (IR), gas and liquid chromatography
(GC and LC), thin-layer chromatography (TLC)
and recently, capillary electrophoresis (CE) [1].
CE has proved to possess several advantages
over other techniques like LC, e.g. higher effi-
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Fig. 1. Chemical structure of naproxen.
system in a phosphoric acid:triethanolamine pH 3
buffer. The influence of the nature and concentra-
tion of CDs (alone and in combination) has been
first studied with the aim of obtaining high enan-
tiomeric resolution within short analysis times.
The developed method has been then validated by
assessing a variety of performance criteria [13–
17]. The criteria evaluated include selectivity, lin-
earity, accuracy and precision.
2. Experimental
2.1. Apparatus
All experiments were performed on a Spec-
traphoresis 1000 CE instrument (SpectraPhysics,
San Jose, CA) equipped with an automatic injec-
tor, an autosampler, a variable wavelength UV-
visible absorbance detector (190–800 nm) and a
temperature control system (15–60°C). The pH of
running buffers was measured by means of a
Delta 345 pH-meter from Mettler (Halstead,
UK).
2.2. Chemicals and reagents
Heptakis (2,6-di-O-methyl)-b-cyclodextrin (di-
methyl-b-cyclodextrin: DMCD) and heptakis (2,
3, 6-tri-O-methyl)-b-cyclodextrin (trimethyl-b-cy-
clodextrin: TMCD) were from Sigma (St Louis,
MO). Carboxymethyl-b-cyclodextrin (CMCD)
was from Cyclolab (Budapest, Hungary). Sul-
fobutyl-b-cyclodextrin (SBCD) was kindly pro-
vided by Professor Stobaugh (University of
Kansas, Laurence, KS).
ciency, shorter analysis time, faster method devel-
opment and lower consumption of chiral selector
and sample [2–4]. Among several approaches, the
addition of cyclodextrins (CDs) as chiral selectors
to the background electrolyte (BGE) in CE seems
the method of choice for the enantioresolution of
drugs. Chiral separation is possible because differ-
ent degrees in complexation between the two
enantiomers and the chiral selector result in mo-
bility differences [4].
Relatively few papers have discussed the valida-
tion of chiral CE methods for routine analysis,
although such information is becoming more
available as CE matures [3–9].
In previous works, complete enantiomeric sepa-
ration of naproxen, a non-steroidal anti-inflam-
matory drug (NSAID), was obtained using a
neutral CD in buffers having a pH close to the
pKa of the analyte (pH 5), the electroosmotic flow
being suppressed by the addition of hydroxyethyl-
cellulose [10] or a hydrophilic linear polymer [7].
A series of chiral acidic compounds containing
carboxy groups, such as NSAIDs, were also enan-
tioseparated by simultaneous addition of anionic
and uncharged b-CD derivatives to a phosphoric
acid:triethanolamine pH 3 buffer [11,12].
In this paper, a simple CE method for the
enantiomeric purity control of S-naproxen in a
formulation has been developed using a dual CD
Table 1




a Buffer, 100 mM phosphoric acid:triethanolamine (pH 3) containing SBCD (5 mM) or CMCD (10 mM) and a neutral CD:
DMCD or TMCD (10 mM); voltage, 25 kV; temperature, 25°C; wavelength, 210 nm; hydrodynamic injection, 5 s; sample, 20 mg
ml1.
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Fig. 2. Enantioseparation of naproxen. Buffer: 100 mM phosphoric acid:triethanolamine (pH 3) containing SBCD (5 mM) and
TMCD (20 mM). Hydrodynamic injection: 5 s. Sample: 20 mg ml1 of racemic naproxen in water:methanol (7:3).
Phosphoric acid (85%) and triethanolamine
were of analytical reagent grade from Merck
(Darmstadt, Germany). Water was of milli-Q
quality (Millipore Corporation, Bedford, MA)
and methanol was of HPLC grade from Acros
(Geel, Belgium). S-naproxen were from Sigma
and the racemic mixture of naproxen was kindly
provided by Professor Blaschke (University of
Mu¨nster, Germany).
All solutions were filtered through a 0.20 mm
pore size filter (Schleicher and Schuell, Keene,
NH).
2.3. Electrophoretic technique
Electrophoretic separations were carried out
with uncoated fused silica capillaries, 50 mm inter-
nal diameter and 44 cm length (37 cm to the
detector), provided by Supelco (Bellefonte, PA).
The capillary was pretreated successively with al-
kaline solutions (NaOH 1 M, NaOH 0.1 M),
water and running buffer. At the beginning of
each working day, the capillary was rinsed with
running buffer for 10 min. Between each injection,
the capillary was rinsed with buffer for 3 min
(6 volumes of the capillary). The applied
voltage was 25 kV (detector at the anode end
of the capillary). UV detection was performed at
210 nm and injections were made in hydrody-
namic mode for a period of 5 s during the optimi-
sation step (corresponding to 13.3 nl) and for the
S-naproxen determination. For the enantiomeric
purity determination, the injection time was 12 s.
The capillary was thermostatted at 25°C. For the
electrophoretic experiments, a buffer made of 100
mM phosphoric acid adjusted to pH 3.0 with
triethanolamine was used.
The resolution (Rs) and plate number (N) were
calculated according to the standard expressions
based on the peak width at half height [18].
2.4. Sample solutions
For the optimisation step, the standard solution
was prepared by dissolving the racemic mixture of
naproxen at a concentration of 5105 M (20
mg ml1) in a mixture of water and methanol
(7:3).
The average weight of one tablet was 935.42 mg
and as declared, contained 500 mg of S-naproxen
and several excipients, in particular citric acid,
cellulose and methacrylate ammonium copolymer.
For the determination of R-naproxen (enan-
tiomeric impurity), standard solutions were pre-
pared by dissolving the racemic mixture of
naproxen at five concentrations (1.4, 7, 14, 21, 28
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Fig. 3. Enantiomeric purity testing of S-naproxen. Buffer: 100 mM phosphoric acid:triethanolamine (pH 3) containing SBCD (5
mM) and TMCD (20 mM). Hydrodynamic injection: 12 s. Sample: 700 mg ml1 of S-naproxen in water:methanol (7:3).
mg ml1) corresponding to five calibration levels
(n5) in a mixture of water and methanol (7:3).
The same handling procedure was then applied
to five synthetic mixtures of the dosage form
excipients to which the corresponding amount of
naproxen was added (spiked placebos) in order to
search for possible interferences from excipients
over the calibration range tested.
For S-naproxen determination, standard and
spiked placebo solutions were prepared by dis-
solving the S-naproxen reference standard at five
concentrations (40, 60, 80, 100 and 120 mg ml1)
in a mixture of water and methanol (7:3).
3. Results and discussion
3.1. Optimisation of naproxen enantioseparation
All enantiomeric separations reported were per-
formed at 25°C using buffers made of 100 mM
phosphoric acid adjusted to pH 3.0 with tri-
ethanolamine and containing one or two b-cy-
clodextrin derivatives. In previous papers, we
demonstrated the suitability of this kind of BGE
for the enantiomeric separation of basic, acidic
and even neutral drugs [6,11,12,19].
The pH 3 buffer was here tested for the enan-
tioseparation of the non-steroidal anti-inflamma-
tory drug (NSAID) naproxen. The chemical
structure of this drug is given in Fig. 1.
In such a low pH buffer, the acidic naproxen
(pKa4.2) was mainly present in uncharged
form and therefore was migrating close to the
electroosmotic flow (low but anodic [6]), the latter
making its detection possible at the anodic side of
the capillary (reversed polarity mode). Under
these conditions, no enantiomeric separation
could be expected for this acidic compound from
the addition of a neutral cyclodextrin alone
(DMCD: dimethyl-b-cyclodextrin or TMCD:
trimethyl-b-cyclodextrin). Indeed, even in the
presence of enantioselective interactions with this
kind of cyclodextrin, no chiral resolution would
be observed, due to the lack of significant mobil-
ity difference between the free and complex forms
of the analyte enantiomers.
On the contrary, the use of a negatively charged
b-cyclodextrin derivative (SBCD: sulfobutyl-b-
cyclodextrin or CMCD: carboxymethyl-b-cy-
clodextrin) was found to give rise to the
formation of complexes migrating electrophoreti-
cally towards the anode and consequently this
could lead to the enantiomeric resolution of the
drug. As shown in Table 1, naproxen enantiomers
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were partly resolved in the presence of 5 mM
SBCD (Rs1.0) and in the presence of 10 mM
CMCD (RsB0.7).
The two anionic cyclodextrin derivatives
(SBCD and CMCD) were then tested as chiral
additives at different concentrations for the enan-
tioseparation of the acidic drug at pH 3. Resolu-
tion values obtained with SBCD and CMCD were
fairly constant in the whole concentration range
studied (1–10 mM, results not shown here). With
both cyclodextrins, a decrease in analyte migra-
tion times was observed with increasing selector
concentration since the proportion of negatively
charged complexes was increased. A 5 mM con-
centration of SBCD and a 10 mM concentration
of CMCD were found to give the analyte enan-
tiomers appropriate migration times (B10 min)
and these concentrations were kept constant in all
further experiments.
Table 3







Coefficient of determination (r2) 0.9994
Accuracy (k3, n6)
Mean recovery 9CI (%) at 50% 100.092.9
99.490.9100%
99.690.9150%









Validation results for R-naproxen (enantiomeric impurity)a
R-naproxen





Coefficient of determination (r2) 0.9957
LOD–LOQ
0.03Limit of detection (%)
Limit of detection (ng ml1) 210
0.10Limit of quantitation (%)
700Limit of quantitation (ng ml1)
Accuracy (k3, n6)
92.798.8Mean recovery 9CI (%) at 0.1%
100.894.3Mean recovery 9CI (%) at 1.0%
Mean recovery 9CI (%) at 2.0% 99.892.3








a CI, confidence interval.
Dual CD systems, using a mixture of a neutral
CD (DMCD or TMCD at 10 mM concentration)
and a charged CD (SBCD or CMCD, at a con-
centration of 5 or 10 mM, respectively), were then
investigated. For all combinations tested (SBCD:
DMCD, SBCD:TMCD, CMCD:DMCD and
CMCD:TMCD), resolution values were higher
than those achieved with a system containing only
SBCD or CMCD (Table 1). This could be ex-
plained by a high selectivity for the enantiosepara-
tion resulting from the complexation of the drug
in uncharged form with the neutral cyclodextrins
while interactions with the charged CDs gave only
rise to low chiral resolution (Rs51.0).
Among the two neutral cyclodextrins tested,
TMCD was found to be the most suited to the
enantioseparation of naproxen, especially with
SBCD (Table 1, Rs4.1).
The next step in our investigation was to study
the influence on enantioresolution of the concen-
tration of TMCD added to the pH 3 buffer
containing 5 mM SBCD. Resolution values were
found to increase with TMCD concentration (re-
sults not presented here). As shown in Fig. 2, a
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excellent separation (Rs5.4 and migration times
B10 min) was achieved using 20 mM TMCD.
3.2. Validation of the method de6eloped for the
determination of R-naproxen (enantiomeric
impurity)
Under the selected operating conditions (pH 3
buffer made of 100 mM phosphoric acid:tri-
ethanolamine containing 5 mM SBCD and 20
mM TMCD), the method was validated for the
determination of R-naproxen (enantiomeric impu-
rity) using the racemic mixture of the analyte (Fig.
3).
3.2.1. Selecti6ity
No interference from the formulation excipients
could be observed at the migration times of the
enantiomers. The migration order (R-enantiomer
migrating first) was confirmed by spiking
experiments.
3.2.2. Linearity
Calibration graphs were constructed at five
concentration levels in the range 0.1–2.0% of the
nominal concentration of S-naproxen in the
tablets, and three independent determinations
were performed at each concentration (n3).
Linear regression lines were obtained by plotting
the normalised peak areas (ratios of peak areas to
migration times) versus the analyte concentration
using the least squares method.
Firstly, the linearity of the calibration curve for
R-naproxen in water:methanol (7:3) solution
(standard solution) was determined. A straight
line passing through the origin and coefficient of
determination (r2) of 0.9969 were obtained. The
linearity was also confirmed by an analysis of
variance (ANOVA) [15,16]. The same statistical
approach was then applied to a synthetic mixture
of the excipients of the dosage form to which
known quantities of racemic naproxen were added
(spiked placebos) corresponding to the different
concentration levels in the range tested. The re-
gression parameters are given in Table 2. As
earlier, the regression lines were obtained by using
the least squares method according to the hypoth-
esis of homoscedasticity [15,16].
3.2.3. Limits of detection and of quantitation
Limits of detection (LOD) and of quantitation
(LOQ), corresponding to signal-to-noise ratios of
3 and 10, respectively, were calculated from linear
regression analysis performed by plotting the ana-
lyte peak height versus the percentage of impurity.
The LOD, the lowest concentration of R-
naproxen that could be detected, was 0.03%,
which corresponds to a concentration of 0.21 mg
ml1 and an amount injected of 7.3 pg or 32
fmol. The LOQ, the lowest concentration of R-
naproxen that could be determined in a purity
determination, was 0.10%, which corresponds to a
concentration of 0.70 mg ml1 and an amount
injected of 24.4 pg or 106 fmol.
3.2.4. Accuracy
Method accuracy was determined by analysing
a placebo spiked with racemic naproxen at three
concentration levels (n6) covering the same
range as that used for linearity (0.1; 1.0; 2.0%).
Mean recoveries with 95% confidence intervals
(CI) are given in Table 2. As the theoretical value
of 100% was included in the confidence interval,
the test procedure could be considered accurate
over the range studied.
3.2.5. Precision
Method precision was determined by measuring
repeatability and intermediate precision (between-
day precision) for R-naproxen in spiked placebos
(n6). The study was carried out over 3 days
(k3) at three concentration levels (0.1; 1.0;
2.0%). The RSD values were estimated from re-
peatability and intermediate precision variances,
respectively [16,17].
As can be seen in Table 2, acceptable results
with respect to precision were obtained. The
RSDs at the LOQ (0.1%) are relatively high but
still acceptable for such low levels of impurity.
The S-naproxen reference standard was found
to contain 0.93% of the R isomer (Fig. 2).
3.3. Validation of the method de6eloped for the
determination of S-naproxen (acti6e drug)
A second validation was performed in the range
50–150% of the nominal concentration of S-
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naproxen in the tablets, the five calibration points
being injected in triplicate.
The same statistical approach as that described
for the R-naproxen determination was used. As can
be seen in Table 3, the adequate linearity of the
calibration graphs is demonstrated by the determi-
nation coefficients (r2\0.999).
The slopes and intercepts of the graphs for
standards and spiked placebos, respectively, were
found to be not significantly different, with tcalcB
2.05 (p0.05) [15,16]. According to the results of
this statistical test, it can be concluded that there
is no matrix effect and a single-level calibration
corresponding to the labelled amount of naproxen
could be used in routine analysis.
As can be seen in Table 3, the test procedure
could be considered accurate over the range stud-
ied. Furthermore, RSD values were estimated at
three concentration levels (50, 100, 150%) from
repeatability and intermediate precision variances
and were in all cases 52%.
3.4. Quantitati6e analysis of a commercial
naproxen tablet
The S-naproxen content in tablets was quantified
by the CE method described above and was found
to be equal to 98.6% of the label claim.
The R-naproxen content in a commercial tablet
formulation was also quantified by the developed
CE method. 0.61% of R-naproxen was found in the
tablets containing S-naproxen.
4. Conclusions
A dual cyclodextrin system using the polyanionic
SBCD in combination with the neutral TMCD in
a pH 3 phosphoric acid:triethanolamine buffer,
was found to be effective for the enantioseparation
of naproxen. In these conditions, excellent resolu-
tion value was obtained within short migration
times (Fig. 2).
The CE method developed was successfully ap-
plied to the quantitation of S-naproxen and R-
naproxen (enantiomeric impurity) in a pharm-
aceutical formulation. Results obtained in method
validation confirm that CE can be considered as an
interesting and cost effective alternative to liquid
chromatography for the quality control of chiral
drugs.
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